ReviewJournal of neuro-oncology1994
Prognostic significance of proteolytic enzymes in human brain tumors.
Review in Journal of neuro-oncology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 75 citations in OpenAlex.
- Urokinase Plasminogen Activator Receptor: An Important Focal Player in Chronic Subdural Hematoma?Inflammation · 2024Article
- To Explore the Stem Cells Homing to GBM: The Rise to the Occasion.Biomedicines · 2022Review
- Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme.International journal of molecular sciences · 2021Review
- Diffuse vertebral metastases from glioblastoma with vertebroepidural diffusion: A case report and review of the literature.Surgical neurology international · 2021Article
- Is DNA Methylation a Ray of Sunshine in Predicting Meningioma Prognosis?Frontiers in oncology · 2020Article
- Correlation of the invasive potential of glioblastoma and expression of caveola-forming proteins caveolin-1 and CAVIN1.Journal of neuro-oncology · 2019Article
- A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1.Neuro-oncology · 2014Article
- ProBDNF and its receptors are upregulated in glioma and inhibit the growth of glioma cells in vitro.Neuro-oncology · 2013Article
- Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.Journal of clinical laboratory analysis · 2012Article
- The molecular biology of brain metastasis.Journal of oncology · 2012Article
- uPA/PAI-1 expression and uPA promoter methylation in meningiomas.Journal of neuro-oncology · 2011Article
- Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy.NeuroImage · 2009Article
- Proteases and glioma angiogenesis.Brain pathology (Zurich, Switzerland) · 2005Review
- Bone marrow metastases from glioblastoma multiforme--A case report and review of the literature.Journal of neuro-oncology · 2005Review
- Pathobiology of brain metastases.Journal of clinical pathology · 2005Review
- Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1.Clinical & experimental metastasis · 2003Article
- Lack of evidence of osteo-medullary metastases at diagnosis in patients with high grade gliomas.Journal of neuro-oncology · 2001Article
- High tPA-expression in primary melanoma of the limb correlates with good prognosis.British journal of cancer · 2000Article
- Article
- Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms.Journal of neuro-oncology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Proteases and their inhibitors have been shown to play roles in tumor invasion and metastasis in a number of experimental models. Recently, relative increases in the amounts of urokinase type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) in tumor samples have been correlated with poorer, pathological grade, shorter disease-free interval, and shorter survival. To date, all studies investigating the prognostic significance of proteases and their inhibitors have been limited to extracranial cancer. In this article, we review the literature and present our data on the prognostic significance of proteases in human brain tumors. High levels of uPA were seen in malignant glioma and metastatic tumors (n = 82), whereas normal levels of uPA were found in low-grade gliomas. Analysis with magnetic resonance imaging (MRI) demonstrated a significant correlation between high levels of uPA and necrosis and edema (n = 50; P < 0.05). Similarly, patients with high levels of uPA had shorter survival than did patients with low levels of uPA. Tissue-type plasminogen activator (tPA), which was virtually absent in glioblastoma multiforme (GBM), colon lung, and breast metastasis, was found in normal quantities in anaplastic astrocytoma (AA), low-grade glioma (LGG), and meningioma. Melanoma had significantly more tPA activity than normal brain did. A reverse correlation was found between tPA and MRI findings of necrosis, enhancement, and edema. Similarly, patients with no detectable tPA activity had shorter survival than did patients with detectable tPA activity. We conclude that high levels of uPA and absent tPA activity correlate with histologically malignant brain tumors, aggressive characteristics, and shorter survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.